275% lower IL-1β — the molecular fingerprint
A direct measurement of inflammation in the wound, not just a pain score moving.
The finding
Beyond pain and drug use, Rhode 2010 measured interleukin-1β — a primary inflammatory signaling molecule — directly in wound exudate. In treated patients it ran markedly lower at one hour (the ~275% figure shown on the site) and stayed suppressed through the first day.
Why this is the most important number
Pain scores are subjective; a cytokine concentration measured in the wound is not. The IL-1β drop is the molecular fingerprint of the nitric-oxide anti-inflammatory pathway actually working in a real surgical wound. It is what connects the clinical effect to the mechanism — and it is the reason the result is hard to dismiss as placebo.
The study design
IL-1β was collected from wound drain fluid — fluid that drains from the surgical site in the first post-operative hours. This is not a serum measurement or a proxy; it is direct sampling of the tissue environment at the site of treatment. Measurements were taken at 1 and 24 hours. The fact that the treated group showed markedly lower IL-1β at both timepoints, in the same patients who showed lower pain and lower narcotic use, provides triangulation: three independent measures of the same underlying process all moved in the same direction.
What this means in practice
Interleukin-1β is not just a bystander — it is an active driver of the local pain and inflammatory cycle. Lower IL-1β means less pro-inflammatory prostaglandin synthesis, less sensitization of local pain receptors (peripheral sensitization), and a reduced inflammatory signal driving the recruitment of additional immune cells. Suppressing IL-1β in the wound is not a comfort measure — it is interrupting the chemical process that sustains post-operative pain and edema.
Compared to the standard alternative
NSAIDs reduce prostaglandin synthesis downstream of IL-1β signaling but do not reduce IL-1β itself — they suppress one downstream branch. tPEMF, operating through the nitric-oxide cascade, reduces IL-1β at a more upstream point in the inflammatory pathway. These are complementary mechanisms rather than duplicative ones, which is why the effect of adding tPEMF to a standard multimodal regimen is additive rather than redundant.
Sources
- Rhode C, et al. Plast Reconstr Surg. 2010 — IL-1β in wound exudate
Related
Ready to put SofPulse to work?
SofPulse is available by prescription. Patients can order online and pay with pre-tax HSA/FSA dollars; clinicians can start prescribing in minutes.
For education only — not medical advice, and not a substitute for a clinician's judgment. SofPulse is available by prescription only. Reimbursement figures reflect the 2026 CMS Physician Fee Schedule and vary by locality, payer, and documentation.